CRDF 10-Q Quarterly Report Sept. 30, 2022 | Alphaminr
Cardiff Oncology, Inc.
ALPHAMINR

CRDF 10-Q Quarter ended Sept. 30, 2022

Balance Sheet
Cash Flow
Income Statement
CARDIFF ONCOLOGY, INC.
10-Ks and 10-Qs
10-Q
Quarter ended Sept. 30, 2025
10-Q
Quarter ended June 30, 2025
10-Q
Quarter ended March 31, 2025
10-K
Fiscal year ended Dec. 31, 2024
10-Q
Quarter ended Sept. 30, 2024
10-Q
Quarter ended June 30, 2024
10-Q
Quarter ended March 31, 2024
10-K
Fiscal year ended Dec. 31, 2023
10-Q
Quarter ended Sept. 30, 2023
10-Q
Quarter ended June 30, 2023
10-Q
Quarter ended March 31, 2023
10-K
Fiscal year ended Dec. 31, 2022
10-Q
Quarter ended Sept. 30, 2022
10-Q
Quarter ended June 30, 2022
10-Q
Quarter ended March 31, 2022
10-K
Fiscal year ended Dec. 31, 2021
10-Q
Quarter ended Sept. 30, 2021
10-Q
Quarter ended June 30, 2021
10-Q
Quarter ended March 31, 2021
10-K
Fiscal year ended Dec. 31, 2020
10-Q
Quarter ended Sept. 30, 2020
10-Q
Quarter ended June 30, 2020
10-Q
Quarter ended March 31, 2020
10-K
Fiscal year ended Dec. 31, 2019
10-Q
Quarter ended Sept. 30, 2019
10-Q
Quarter ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-K
Fiscal year ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2018
10-Q
Quarter ended June 30, 2018
10-Q
Quarter ended March 31, 2018
10-K
Fiscal year ended Dec. 31, 2017
10-Q
Quarter ended Sept. 30, 2017
10-Q
Quarter ended June 30, 2017
10-Q
Quarter ended March 31, 2017
10-K
Fiscal year ended Dec. 31, 2016
10-Q
Quarter ended Sept. 30, 2016
10-Q
Quarter ended June 30, 2016
10-Q
Quarter ended March 31, 2016
10-K
Fiscal year ended Dec. 31, 2015
10-Q
Quarter ended Sept. 30, 2015
10-Q
Quarter ended June 30, 2015
10-Q
Quarter ended March 31, 2015
10-K
Fiscal year ended Dec. 31, 2014
10-Q
Quarter ended Sept. 30, 2014
10-Q
Quarter ended June 30, 2014
10-Q
Quarter ended March 31, 2014
10-K
Fiscal year ended Dec. 31, 2013
10-Q
Quarter ended Sept. 30, 2013
10-Q
Quarter ended June 30, 2013
10-Q
Quarter ended March 31, 2013
10-K
Fiscal year ended Dec. 31, 2012
10-Q
Quarter ended Sept. 30, 2012
10-Q
Quarter ended June 30, 2012
10-Q
Quarter ended March 31, 2012
10-K
Fiscal year ended Dec. 31, 2011
PROXIES
DEF 14A
Filed on April 29, 2025
DEF 14A
Filed on June 20, 2024
DEF 14A
Filed on April 25, 2024
DEF 14A
Filed on April 27, 2023
DEF 14A
Filed on June 9, 2022
DEF 14A
Filed on April 14, 2022
DEF 14A
Filed on April 28, 2021
DEF 14A
Filed on March 4, 2020
DEF 14A
Filed on April 19, 2019
DEF 14A
Filed on Dec. 18, 2018
DEF 14A
Filed on April 27, 2018
DEF 14A
Filed on April 28, 2017
DEF 14A
Filed on March 31, 2016
DEF 14A
Filed on Oct. 16, 2015
DEF 14A
Filed on April 20, 2015
DEF 14A
Filed on July 23, 2014
DEF 14A
Filed on May 29, 2013
DEF 14A
Filed on Oct. 18, 2012
DEF 14A
Filed on March 20, 2012
crdf-20220930
0001213037 FALSE 12/31 2022 Q3 0001213037 2022-01-01 2022-09-30 0001213037 2022-10-27 xbrli:shares 0001213037 2022-09-30 iso4217:USD 0001213037 2021-12-31 iso4217:USD xbrli:shares 0001213037 2022-07-01 2022-09-30 0001213037 2021-07-01 2021-09-30 0001213037 2021-01-01 2021-09-30 0001213037 us-gaap:PreferredStockMember 2021-12-31 0001213037 us-gaap:CommonStockMember 2021-12-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001213037 crdf:ServiceReceivableMember 2021-12-31 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001213037 us-gaap:RetainedEarningsMember 2021-12-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001213037 2022-01-01 2022-03-31 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001213037 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001213037 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001213037 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001213037 crdf:ServiceReceivableMember 2022-01-01 2022-03-31 0001213037 us-gaap:PreferredStockMember 2022-03-31 0001213037 us-gaap:CommonStockMember 2022-03-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001213037 crdf:ServiceReceivableMember 2022-03-31 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001213037 us-gaap:RetainedEarningsMember 2022-03-31 0001213037 2022-03-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001213037 2022-04-01 2022-06-30 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001213037 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001213037 us-gaap:PreferredStockMember 2022-06-30 0001213037 us-gaap:CommonStockMember 2022-06-30 0001213037 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001213037 crdf:ServiceReceivableMember 2022-06-30 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001213037 us-gaap:RetainedEarningsMember 2022-06-30 0001213037 2022-06-30 0001213037 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001213037 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001213037 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001213037 us-gaap:PreferredStockMember 2022-09-30 0001213037 us-gaap:CommonStockMember 2022-09-30 0001213037 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001213037 crdf:ServiceReceivableMember 2022-09-30 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001213037 us-gaap:RetainedEarningsMember 2022-09-30 0001213037 us-gaap:PreferredStockMember 2020-12-31 0001213037 us-gaap:CommonStockMember 2020-12-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001213037 crdf:ServiceReceivableMember 2020-12-31 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001213037 us-gaap:RetainedEarningsMember 2020-12-31 0001213037 2020-12-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001213037 2021-01-01 2021-03-31 0001213037 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001213037 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001213037 crdf:ServiceReceivableMember 2021-01-01 2021-03-31 0001213037 us-gaap:PreferredStockMember 2021-03-31 0001213037 us-gaap:CommonStockMember 2021-03-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001213037 crdf:ServiceReceivableMember 2021-03-31 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001213037 us-gaap:RetainedEarningsMember 2021-03-31 0001213037 2021-03-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001213037 2021-04-01 2021-06-30 0001213037 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001213037 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001213037 crdf:ServiceReceivableMember 2021-04-01 2021-06-30 0001213037 us-gaap:PreferredStockMember 2021-06-30 0001213037 us-gaap:CommonStockMember 2021-06-30 0001213037 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001213037 crdf:ServiceReceivableMember 2021-06-30 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001213037 us-gaap:RetainedEarningsMember 2021-06-30 0001213037 2021-06-30 0001213037 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001213037 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001213037 crdf:ServiceReceivableMember 2021-07-01 2021-09-30 0001213037 us-gaap:PreferredStockMember 2021-09-30 0001213037 us-gaap:CommonStockMember 2021-09-30 0001213037 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001213037 crdf:ServiceReceivableMember 2021-09-30 0001213037 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001213037 us-gaap:RetainedEarningsMember 2021-09-30 0001213037 2021-09-30 0001213037 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001213037 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001213037 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001213037 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001213037 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-09-30 0001213037 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-09-30 0001213037 crdf:SeriesEConvertiblePreferredStockMember 2022-01-01 2022-09-30 0001213037 crdf:SeriesEConvertiblePreferredStockMember 2021-01-01 2021-09-30 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0001213037 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-09-30 0001213037 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-09-30 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-09-30 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0001213037 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001213037 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001213037 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001213037 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0001213037 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001213037 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001213037 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001213037 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001213037 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0001213037 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-09-30 0001213037 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-09-30 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-09-30 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0001213037 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0001213037 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001213037 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001213037 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001213037 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001213037 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001213037 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001213037 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001213037 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001213037 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001213037 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001213037 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001213037 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001213037 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001213037 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001213037 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001213037 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001213037 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001213037 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001213037 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001213037 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001213037 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001213037 us-gaap:CertificatesOfDepositMember 2022-09-30 0001213037 us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001213037 us-gaap:CommercialPaperMember 2022-09-30 0001213037 us-gaap:USTreasurySecuritiesMember 2022-09-30 0001213037 us-gaap:CertificatesOfDepositMember 2021-12-31 0001213037 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001213037 us-gaap:CommercialPaperMember 2021-12-31 0001213037 us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-12-31 0001213037 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001213037 crdf:FurnitureAndOfficeEquipmentMember 2022-09-30 0001213037 crdf:FurnitureAndOfficeEquipmentMember 2021-12-31 0001213037 us-gaap:LeaseholdImprovementsMember 2022-09-30 0001213037 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001213037 us-gaap:EquipmentMember 2022-09-30 0001213037 us-gaap:EquipmentMember 2021-12-31 utr:sqft xbrli:pure 0001213037 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001213037 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001213037 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001213037 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001213037 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0001213037 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0001213037 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0001213037 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0001213037 us-gaap:EmployeeStockOptionMember 2022-09-30 0001213037 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001213037 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001213037 us-gaap:EmployeeStockOptionMember 2021-12-31 0001213037 2022-06-09 0001213037 crdf:EquityIncentivePlan2021Member 2022-09-30 0001213037 crdf:InducementGrantStockOptionsMember 2022-07-01 2022-09-30 0001213037 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001213037 2022-01-01 2022-06-30 0001213037 crdf:SeriesAConvertiblePreferredStockMember 2022-09-30 0001213037 crdf:SeriesAConvertiblePreferredStockMember 2021-12-31 0001213037 crdf:SeriesBConvertiblePreferredStockMember 2022-09-30 0001213037 crdf:SeriesBConvertiblePreferredStockMember 2021-12-31 0001213037 crdf:SeriesCConvertiblePreferredStockMember 2022-09-30 0001213037 crdf:SeriesCConvertiblePreferredStockMember 2021-12-31 0001213037 crdf:SeriesDConvertiblePreferredStockMember 2022-09-30 0001213037 crdf:SeriesDConvertiblePreferredStockMember 2021-12-31 0001213037 crdf:SeriesEConvertiblePreferredStockMember 2022-09-30 0001213037 crdf:SeriesEConvertiblePreferredStockMember 2021-12-31 0001213037 us-gaap:SubsequentEventMember crdf:SeriesEConvertiblePreferredStockMember 2022-10-11 2022-10-11 0001213037 us-gaap:SubsequentEventMember 2022-10-11 2022-10-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from             to
COMMISSION FILE NUMBER 001-35558
CARDIFF ONCOLOGY, INC.
(Exact Name of registrant as specified in its charter)
Delaware 27-2004382
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
11055 Flintkote Avenue , San Diego , California
92121
(Address of principal executive offices) (Zip Code)
( 858 ) 952-7570
(Registrant’s telephone number, including area code)
Title of each class: Trading Symbol(s) Name of each exchange on which registered:
Common Stock CRDF Nasdaq Capital Market
Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒

Smaller reporting company ☒
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of October 27, 2022, the issuer had 44,677,169 shares of Common Stock issued and outstanding.

CARDIFF ONCOLOGY, INC.
Table of Contents
Page

2
PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CARDIFF ONCOLOGY, INC.
CONDENSED BALANCE SHEETS
(in thousands, except par value)
(Unaudited)
September 30,
2022 		December 31,
2021
Assets
Current assets:
Cash and cash equivalents $ 18,717 $ 11,943
Short-term investments 95,586 128,878
Accounts receivable and unbilled receivable 650 535
Prepaid expenses and other current assets 4,802 4,771
Total current assets 119,755 146,127
Property and equipment, net 1,304 382
Operating lease right-of-use assets 2,388 2,796
Other assets 184 239
Total Assets $ 123,631 $ 149,544
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable $ 1,425 $ 1,439
Accrued liabilities 6,138 4,527
Operating lease liabilities 674 551
Other current liabilities 8 42
Total current liabilities 8,245 6,559
Operating lease liabilities, net of current portion 2,174 2,568
Total Liabilities 10,419 9,127
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred stock, 20,000 shares authorized; (Note 6)
— 1
Common stock, $ 0.0001 par value, 150,000 shares authorized; 43,335 and 41,964 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively
4 4
Additional paid-in capital 403,822 400,503
Service receivables — ( 139 )
Accumulated other comprehensive loss ( 779 ) ( 142 )
Accumulated deficit ( 289,835 ) ( 259,810 )
Total stockholders’ equity 113,212 140,417
Total liabilities and stockholders’ equity $ 123,631 $ 149,544
See accompanying notes to the unaudited condensed financial statements.
3
CARDIFF ONCOLOGY, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Royalty revenues $ 93 $ 86 $ 258 $ 226
Costs and expenses:
Research and development 6,009 4,154 20,665 11,552
Selling, general and administrative 3,077 2,930 10,103 8,003
Total operating expenses 9,086 7,084 30,768 19,555
Loss from operations ( 8,993 ) ( 6,998 ) ( 30,510 ) ( 19,329 )
Other income (expense), net:
Interest income, net 458 70 841 185
Gain from change in fair value of derivative financial instruments—warrants — 12 — 280
Other income (expense), net ( 36 ) 3 ( 338 ) 15
Total other income (expense), net 422 85 503 480
Net loss ( 8,571 ) ( 6,913 ) ( 30,007 ) ( 18,849 )
Preferred stock dividend payable on Series A Convertible Preferred Stock ( 6 ) ( 6 ) ( 18 ) ( 18 )
Net loss attributable to common stockholders $ ( 8,577 ) $ ( 6,919 ) $ ( 30,025 ) $ ( 18,867 )
Net loss per common share — basic and diluted $ ( 0.20 ) $ ( 0.17 ) $ ( 0.69 ) $ ( 0.49 )
Weighted-average shares outstanding — basic and diluted 43,333 39,552 43,291 38,501
See accompanying notes to the unaudited condensed financial statements.

4

CARDIFF ONCOLOGY, INC.
CONDENSED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands)
(Unaudited)

Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Net loss $ ( 8,571 ) $ ( 6,913 ) $ ( 30,007 ) $ ( 18,849 )
Other comprehensive loss:
Unrealized gain (loss) on securities available-for-sale 203 26 ( 637 ) 16
Total comprehensive loss ( 8,368 ) ( 6,887 ) ( 30,644 ) ( 18,833 )
Preferred stock dividend payable on Series A Convertible Preferred Stock ( 6 ) ( 6 ) ( 18 ) ( 18 )
Comprehensive loss attributable to common stockholders $ ( 8,374 ) $ ( 6,893 ) $ ( 30,662 ) $ ( 18,851 )

See accompanying notes to the unaudited condensed financial statements.
5
CARDIFF ONCOLOGY, INC.
CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands)
(Unaudited)

Preferred Stock
Shares 		Preferred Stock
Amount 		Common Stock
Shares 		Common Stock
Amount 		Additional
Paid-In Capital 		Service Receivable Accumulated Other Comprehensive Loss Accumulated Deficit Total
Stockholders’ Equity
Balance, January 1, 2022 716 $ 1 41,964 $ 4 $ 400,503 $ ( 139 ) $ ( 142 ) $ ( 259,810 ) $ 140,417
Stock-based compensation — — — — 1,152 — — — 1,152
Other comprehensive loss — — — — — — ( 606 ) — ( 606 )
Issuance of common stock upon conversion of Series E Convertible Preferred Stock ( 328 ) ( 1 ) 1,342 — — — — — ( 1 )
Preferred stock dividend — — — — — — — ( 6 ) ( 6 )
Release of clinical trial funding commitment — — — — — 139 — — 139
Net loss — — — — — — — ( 10,993 ) ( 10,993 )
Balance, March 31, 2022 388 — 43,306 4 401,655 — ( 748 ) ( 270,809 ) 130,102
Stock-based compensation — — — — 1,055 — — — 1,055
Other comprehensive loss — — — — — — ( 234 ) — ( 234 )
Preferred stock dividend — — — — — — — ( 6 ) ( 6 )
Net loss — — — — — — — ( 10,443 ) ( 10,443 )
Balance, June 30, 2022 388 — 43,306 4 402,710 — ( 982 ) ( 281,258 ) 120,474
Stock-based compensation — — — — 1,037 — — — 1,037
Issuance of common stock upon exercise of stock options — — 29 — 75 — — — 75
Other comprehensive gain — — — — — — 203 — 203
Preferred stock dividend — — — — — — — ( 6 ) ( 6 )
Net loss — — — — — — — ( 8,571 ) ( 8,571 )
Balance, September 30, 2022 388 $ — 43,335 $ 4 $ 403,822 $ — $ ( 779 ) $ ( 289,835 ) $ 113,212


6
CARDIFF ONCOLOGY, INC.
CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands)
(Unaudited)

Preferred Stock
Shares 		Preferred Stock
Amount 		Common Stock
Shares 		Common Stock
Amount 		Additional
Paid-In Capital 		Service Receivable Accumulated Other Comprehensive Loss Accumulated Deficit Total
Stockholders’ Equity
Balance, January 1, 2021 716 $ 1 36,781 $ 4 $ 361,819 $ ( 2,171 ) $ — $ ( 231,495 ) $ 128,158
Stock-based compensation — — — — 268 — — — 268
Issuance of common stock upon exercise of warrants — — 771 — 1,263 — — — 1,263
Other comprehensive loss — — — — — — ( 67 ) — ( 67 )
Preferred stock dividend — — — — — — — ( 6 ) ( 6 )
Release of clinical trial funding commitment — — — — — 380 — — 380
Net loss — — — — — — — ( 5,179 ) ( 5,179 )
Balance, March 31, 2021 716 1 37,552 4 363,350 ( 1,791 ) ( 67 ) ( 236,680 ) 124,817
Stock-based compensation — — — — 1,036 — — — 1,036
Sale of common stock, net of expenses (1)
— — 2,000 — 19,225 — — — 19,225
Other comprehensive gain — — — — — — 57 — 57
Preferred stock dividend — — — — — — — ( 6 ) ( 6 )
Release of clinical trial funding commitment — — — — — 546 — — 546
Net loss — — — — — — — ( 6,757 ) ( 6,757 )
Balance, June 30, 2021 716 1 39,552 4 383,611 ( 1,245 ) ( 10 ) ( 243,443 ) 138,918
Stock-based compensation — — — — 940 — — — 940
Other comprehensive gain — — — — — — 26 — 26
Preferred stock dividend — — — — — — — ( 6 ) ( 6 )
Release of clinical trial funding commitment — — — — — 579 — — 579
Net loss — — — — — — — ( 6,913 ) ( 6,913 )
Balance, September 30, 2021 716 $ 1 39,552 $ 4 $ 384,551 $ ( 666 ) $ 16 $ ( 250,362 ) $ 133,544

(1) Net of expenses of $ 0.8 million.

See accompanying notes to the unaudited condensed financial statements.
7
CARDIFF ONCOLOGY, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
Nine Months Ended September 30,
2022 2021
Operating activities
Net loss $ ( 30,007 ) $ ( 18,849 )
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of assets — 1
Depreciation 150 338
Stock-based compensation expense 3,244 2,244
Amortization of premiums on short-term investments 672 1,160
Change in fair value of derivative financial instruments—warrants — ( 280 )
Release of clinical trial funding commitment 139 1,505
Changes in operating assets and liabilities:
Other assets 55 261
Accounts receivable and unbilled receivable ( 115 ) ( 74 )
Prepaid expenses and other assets 4 ( 741 )
Operating lease right-of-use assets 408 386
Accounts payable and accrued expenses 1,325 ( 830 )
Operating lease liabilities ( 271 ) ( 645 )
Other liabilities ( 34 ) ( 126 )
Net cash used in operating activities ( 24,430 ) ( 15,650 )
Investing activities:
Capital expenditures ( 931 ) ( 98 )
Insurance proceeds from casualty loss 114 —
Maturities of short-term investments 61,229 15,101
Purchases of short-term investments ( 80,428 ) ( 146,632 )
Sales of short-term investments 51,145 8,975
Net cash provided by (used in) investing activities 31,129 ( 122,654 )
Financing activities:
Proceeds from sales of common stock, net of expenses of $ 0 and $ 776 , respectively
— 19,225
Proceeds from exercise of options 75 —
Proceeds from exercise of warrants — 1,263
Net cash provided by financing activities 75 20,488
Net change in cash and cash equivalents 6,774 ( 117,816 )
Cash and cash equivalents—Beginning of period 11,943 130,981
Cash and cash equivalents—End of period $ 18,717 $ 13,165
Supplementary disclosure of cash flow activity:
Cash paid for taxes $ 1 $ 1
Supplemental disclosure of non-cash investing and financing activities:
Acquisition of property and equipment included in accounts payable and accrued expenses $ 255 $ —
Preferred stock dividend payable on Series A Convertible Preferred Stock $ 18 $ 18
See accompanying notes to the unaudited condensed financial statements.
8
CARDIFF ONCOLOGY, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(Unaudited)
1. Organization and Basis of Presentation
Business Organization and Overview
Cardiff Oncology, Inc. (“Cardiff Oncology” or the “Company”) headquartered in San Diego, California, is a clinical-stage biotechnology company leveraging Polo-like Kinase 1 (“PLK1”) inhibition to develop novel therapies across a range of cancers. The Company’s lead asset is onvansertib, a PLK1 inhibitor that is being evaluated in combination with standard-of-care therapies in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer. These programs and the Company’s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the standard-of-care alone. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".
Basis of Presentation
The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December 31, 2021, has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2021, included in the Company’s annual report on Form 10-K filed with the SEC on February 24, 2022.

Liquidity

The Company has incurred net losses since its inception and has negative operating cash flows. As of September 30, 2022, the Company had $ 114.3 million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.

For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company’s stockholders may experience additional dilution.

2. Summary of Significant Accounting Policies
During the nine months ended September 30, 2022, there have been no changes to the Company’s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

Net Loss Per Share
Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.

9
The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:
September 30,
2022 2021
Options to purchase Common Stock 5,101,572 3,566,832
Warrants to purchase Common Stock 4,490,159 4,490,159
Series A Convertible Preferred Stock 877 877
Series E Convertible Preferred Stock 1,342,250 2,684,607
10,934,858 10,742,475

Recently Adopted Accounting Pronouncement

In May 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2021-04 ("ASU 2021-04"), Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has prospectively adopted this standard as of January 1, 2022 for periods presented after the adoption. The adoption of ASU 2021-04 did not have a material impact on the Company's financial statements.

Recent Accounting Pronouncement Not Yet Adopted

In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023, for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.

10
3. Fair Value Measurements
The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 30, 2022 and December 31, 2021:
Fair Value Measurements at
September 30, 2022
(in thousands) Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1) 		Significant Other Observable Inputs
(Level 2) 		Significant Unobservable Inputs
(Level 3) 		Total
Assets:
Money market fund $ 18,079 $ — $ — $ 18,079
Total included in cash and cash equivalents 18,079 — — 18,079
Available for sale investments:
Certificate of deposit — 14,202 — 14,202
Corporate debt securities — 55,647 — 55,647
Commercial paper — 10,483 — 10,483
U.S. treasury securities 15,254 — — 15,254
Total available for sale investments (1) 15,254 80,332 — 95,586
Total assets measured at fair value on a recurring basis $ 33,333 $ 80,332 $ — $ 113,665

Fair Value Measurements at
December 31, 2021
(in thousands) Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1) 		Significant Other Observable Inputs
(Level 2) 		Significant Unobservable Inputs
(Level 3) 		Total
Assets:
Money market fund $ 10,990 $ — $ — $ 10,990
Total included in cash and cash equivalents 10,990 $ — — 10,990
Available for sale investments:
Certificate of deposit — 1,260 — 1,260
Corporate debt securities — 88,390 — 88,390
Commercial paper — 14,454 — 14,454
Non U.S. government — 728 — 728
U.S. treasury securities 24,046 — — 24,046
Total available for sale investments (1) 24,046 104,832 — 128,878
Total assets measured at fair value on a recurring basis $ 35,036 $ 104,832 $ — $ 139,868
(1) Included in short-term investments in the accompanying balance sheets.

The Company’s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the nine months ended September 30, 2022 .
11

4. Supplementary Balance Sheet Information

Investments available for sale

Investments available for sale consist of the following:

As of September 30,
2022
(in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value
Maturity less than 1 year:
Certificate of deposit $ 14,285 $ 4 $ ( 87 ) $ 14,202
Corporate debt securities 49,055 3 ( 498 ) 48,560
Commercial paper 10,528 4 ( 49 ) 10,483
U.S. treasury securities 15,348 — ( 94 ) 15,254
Total maturity less than 1 year 89,216 11 ( 728 ) 88,499
Maturity 1 to 2 years:
Corporate debt securities 7,148 4 ( 65 ) 7,087
U.S. treasury securities — — — —
Total maturity 1 to 2 years 7,148 4 ( 65 ) 7,087
Total short-term investments $ 96,364 $ 15 $ ( 793 ) $ 95,586


As of December 31, 2021
(in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value
Maturity less than 1 year:
Certificate of deposit $ 1,260 $ — $ — $ 1,260
Corporate debt securities 58,822 2 ( 38 ) 58,786
Commercial paper 14,453 4 ( 3 ) 14,454
Non U.S. government 728 — — 728
U.S. treasury securities 20,380 — ( 24 ) 20,356
Total maturity less than 1 year 95,643 6 ( 65 ) 95,584
Maturity 1 to 2 years:
Corporate debt securities 29,676 1 ( 73 ) 29,604
U.S. treasury securities 3,701 — ( 11 ) 3,690
Total maturity 1 to 2 years 33,377 1 ( 84 ) 33,294
Total short-term investments $ 129,020 $ 7 $ ( 149 ) $ 128,878

Unrealized losses in investments available for sale debt securities at September 30, 2022, were primarily due to increases in interest rates, not due to increased credit risks associated with specific securities. We do not intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.


12
Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:
As of September 30,
2022
(in thousands) Fair Market Value Gross Unrealized Loss
Corporate debt securities 751 ( 6 )
U.S. treasury securities 1,839 ( 22 )
Total short-term investments $ 2,590 $ ( 28 )

Property and equipment

Property and equipment consist of the following:
(in thousands) As of September 30,
2022 		As of December 31,
2021
Furniture and office equipment $ 1,069 $ 955
Leasehold improvements 2,545 1,962
Laboratory equipment 1,019 906
4,633 3,823
Less—accumulated depreciation and amortization ( 3,329 ) ( 3,441 )
Property and equipment, net $ 1,304 $ 382

Accrued Liabilities

Accrued liabilities consisted of the following:

(in thousands) As of September 30,
2022 		As of December 31,
2021
Accrued compensation $ 1,609 $ 1,435
Preferred stock dividend 432 414
Clinical trials 2,132 1,639
Research agreements and services 1,125 726
Director fees 125 141
Professional fees and outside services 29 63
Patent, license and other fees 122 43
Other accrued liabilities 564 66
Total accrued liabilities $ 6,138 $ 4,527
5. Leases

As a lessee, the Company’s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases.

Master Facility Lease

The Company currently leases 12,300 square feet of office and lab space in San Diego that expires on February 28, 2027. The lease currently requires monthly payments of approximately $ 60,000 per month with 3 % annual escalation.

13
The components of lease expense were as follows:
Three Months Ended September 30, Nine Months Ended September 30,
(in thousands) 2022 2021 2022 2021
Operating lease cost $ 188 $ 281 $ 568 $ 468
Operating sublease income — ( 101 ) — ( 303 )
Net operating lease cost $ 188 $ 180 $ 568 $ 165

Supplemental balance sheet information related to leases was as follows:
(in thousands) As of September 30,
2022 		As of December 31,
2021
Operating lease ROU assets $ 2,388 $ 2,796
Current operating lease liabilities $ 674 $ 551
Non-current operating lease liabilities 2,174 2,568
Total operating lease liabilities $ 2,848 $ 3,119
Weighted-average remaining lease term–operating leases 4.5 years 5.2 years
Weighted-average discount rate–operating leases 7.0 % 7.0 %

Supplemental cash flow and other information related to leases was as follows:
Three Months Ended September 30, Nine Months Ended September 30,
(in thousands) 2022 2021 2022 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases $ 180 $ 243 $ 431 $ 726
ROU assets obtained in exchange for lease liabilities:
Operating leases $ — $ 3,061 $ — $ 3,061

Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:
(in thousands)
Year Ending December 31, Operating Leases
2022 (excluding the nine months ended September 30, 2022)
$ 120
2023 737
2024 754
2025 775
2026 796
Thereafter 137
Total future minimum lease payments 3,319
Less imputed interest ( 471 )
Total $ 2,848

14
6. Stockholders’ Equity
Stock Options
Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:
Three Months Ended September 30, Nine Months Ended September 30,
(in thousands) 2022 2021 2022 2021
Included in research and development expense $ 286 $ 174 $ 746 $ 286
Included in selling, general and administrative expense 751 766 2,498 1,958
Total stock-based compensation expense $ 1,037 $ 940 $ 3,244 $ 2,244
The unrecognized compensation cost related to non-vested stock options outstanding at September 30, 2022, net of estimated forfeitures, was $ 9.8 million, which is expected to be recognized over a weighted-average remaining vesting period of 2.8 years. The weighted-average remaining contractual term of outstanding options as of September 30, 2022, was approximately 7.6 years. The total fair value of stock options vested during the nine months ended September 30, 2022 and 2021, were $ 4.0 million and $ 1.2 million, respectively.

The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:
Nine Months Ended September 30,
2022 2021
Risk-free interest rate 1.87 % 0.95 %
Dividend yield 0 % 0 %
Expected volatility of Cardiff Oncology common stock 106 % 108 %
Expected term 6.0 years 6.0 years

A summary of stock option activity and changes in stock options outstanding is presented below:
Total Options Weighted-Average
Exercise Price
Per Share 		Intrinsic
Value
Balance outstanding, December 31, 2021 3,771,984 $ 7.13 $ 6,405,258
Granted 1,731,136 $ 3.15
Exercised ( 28,858 ) $ 2.60
Canceled / Forfeited ( 371,125 ) $ 4.77
Expired ( 1,565 ) $ 184.73
Balance outstanding, September 30, 2022 5,101,572 $ 5.92 $ 30,739
Exercisable at September 30, 2022 2,178,676 $ 7.44 $ 16,013
Vested and expected to vest at September 30, 2022 5,017,818 $ 5.94 $ 29,723
2021 Equity Incentive Plan

In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 Plan is equal to the sum of (i) 3,150,000 shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. On June 9, 2022 the shareholders approved an increase of shares authorized in the 2021 Plan to 5,150,000 from 3,150,000 . As of September 30, 2022, there were 3,055,281 shares available for issuance under the 2021 Plan.

2014 Equity Incentive Plan
15

Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan.

Inducement Grants

In July 2021, the Company began issuing equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of September 30, 2022, an aggregate of 920,208 shares were issuable upon the exercise of inducement grant stock options approved by the Company.

Modification of Stock Options

In June 2022 one of the Company's directors did not seek another term on the Board of Directors. At the time of departure, the Compensation Committee passed a resolution to extend the expiration date of the vested stock options, and to immediately accelerate the vesting of the unvested options. The Company recorded incremental reduction to stock compensation expense of $ 0.1 million during the nine months ended September 30, 2022, related to the modifications.

Warrants
A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:
Total Warrants Weighted-Average
Exercise Price
Per Share 		Weighted-Average
Remaining Contractual
Term
Balance outstanding, December 31, 2021 4,490,159 $ 5.80 3.0 years
Balance outstanding, September 30, 2022 4,490,159 $ 5.80 2.2 years


Preferred Stock

A summary of our Company's classes of preferred stock is presented below:
Shares outstanding
Class Par value Shares designated Liquidation preference As of September 30,
2022 		As of December 31,
2021
Series A Convertible Preferred Stock $ 0.001 277,100 $ 606,000 60,600 60,600
Series B Convertible Preferred Stock $ 0.001 8,860 None — —
Series C Convertible Preferred Stock $ 0.001 200,000 None — —
Series D Convertible Preferred Stock $ 0.0001 154,670 None — —
Series E Convertible Preferred Stock $ 0.001 865,824 None 327,509 655,044


7. Commitments and Contingencies
Executive Agreements
Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios.
16
Research and Development Agreements

In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Onvansertib, an investigational drug, is an oral, and a highly selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company is developing onvansertib in cancer indications with the greatest medical need for new treatment options. Terms of the agreement provide for the Company to pay development milestones and royalties based on sales volume.
The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The Company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. For the nine months ended September 30, 2022 and 2021, payments have not been material.

Litigation

Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company’s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company’s business or financial condition.

8. Subsequent Events

Conversion of Series E Convertible Preferred Stock

327,509 Series E Convertible Preferred Shares were converted into 1,342,250 shares of common stock on October 11, 2022.

17
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions.
In addition, our business and financial performance may be affected by the factors that are discussed under “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 24, 2022. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
The following discussion and analysis is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the financial statements and the notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best present assessment of our management.
Overview

We are a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance, improve disease response to standard treatment regimens and increase overall survival. We are developing onvansertib, an oral and highly selective PLK1 inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker assays to refine assessment of patient response to treatment.

Our Drug Candidate, Onvansertib

Onvansertib is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life.

We believe the attributes of onvansertib described below, as well as clinical evidence of favorable safety and efficacy, with expected on-target, easy to manage and reversible side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers:

• Onvansertib is highly potent and highly selective against the PLK1 enzyme (IC 50 = 2nM; IC 50 is the concentration for 50% inhibition), compared to prior PLK1 inhibitors that were pan-inhibitors of several PLK targets. Low or no activity of onvansertib was observed on a panel of 63 kinases (IC50>500 nM), including the PLK members PLK2 and PLK3 (IC 50 >10,000 nM);

• Onvansertib has a relatively short drug half-life of 24 hours, allowing for flexible dosing and scheduling which has shown favorable safety and tolerability across multiple clinical trials;
18

• Onvansertib is orally bioavailable, allowing for relative ease and flexibility of dosing.

In vitro studies have shown synergistic effects when onvansertib was administered in combination with different cytotoxic agents including microtubule-targeting agents, topoisomerase 1 inhibitors, antimetabolites, alkylating agents, proteasome inhibitors, kinase inhibitors, BCL-2 inhibitors, and androgen biosynthesis inhibitors.

In addition, in vivo combination studies have confirmed the positive results obtained in vitro and synergistic effects have been observed in xenograft models of onvansertib in combination with irinotecan, 5-fluorouracil ("5-FU"), abiraterone, PARP inhibitors, venetoclax, and paclitaxel, while additive effects in combination with cytarabine or bevacizumab have been demonstrated. Combining onvansertib with standard-of-care cancer agents provides opportunities for synergy with many cancer therapies.

There are five ongoing or soon to be activated clinical trials of onvansertib: two trials (TROV-054 and ONSEMBLE) in second line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer ("mCRC"), one trial in second line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma ("mPDAC"), and two investigator-initiated trials in patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer ("TNBC") and relapsed Small Cell Lung Cancer ("SCLC").

Phase 1b/2 Clinical Trial in KRAS-mutated mCRC

TROV-054 is a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with standard of care FOLFIRI and bevacizumab (Avastin ® ) for the second line treatment of patients with KRAS-mutated mCRC, which is being conducted at seven clinical trial sites across the U.S. - USC Norris Comprehensive Cancer Center, The Mayo Clinic Cancer Centers (Arizona, Minnesota, and Florida), Kansas University Medical Center, Inova Schar Cancer Institute and CARTI Cancer Center.

The primary objectives of this trial are to evaluate the Dose-Limiting Toxicities ("DLTs"), maximum tolerated dose ("MTD") and recommended Phase 2 dose ("RP2D") of onvansertib in combination with FOLFIRI and bevacizumab (Phase 1b) and to continue to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab patients with KRAS-mutated mCRC (Phase 2).

The scientific rationale for this clinical trial is based on the two key principles of synthetic lethality and synergy, with the objective of demonstrating a proof-of-concept of clinical benefit within this phase1b/2 trial. Synthetic lethality refers to a critical vulnerability to tumor cell death by way of PLK1 inhibition within CRC tumor cells harboring KRAS mutations versus KRAS wild-type isogenic cells. Synergy occurs when the combination of two drugs results in an unexpected greater activity than an expected additive effect of the two drugs. Onvansertib in combination with two DNA-damaging agents, irinotecan, and 5-FU (two components of FOLFIRI), demonstrated synergy in colorectal cancer cell lines and both combinations have demonstrated significantly greater tumor growth inhibition than either drug alone in CRC in vivo models. We believe this synergy occurs because PLK1 can promote the repair of DNA damage caused by chemotherapeutic agents and by inhibiting PLK1, onvansertib leaves damaged tumor cells unable to replicate.

Data presented on September 12, 2022 provided an update of the ongoing TROV-054 phase 1b/2 single arm clinical trial in KRAS-mutated metastatic colorectal cancer:

• Objective response rate ("ORR") across all evaluable patients was 35%, with 17 of 48 evaluable patients achieving an objective response. Responses have been observed across multiple KRAS variants;

• Median duration of response ("mDoR") across all evaluable patients was 11.7 months (95% confidence interval ("CI"): 8.9 – not reached);

• Median progression free survival ("mPFS") across all evaluable patients was 9.3 months (95% CI: 7.6 – 13.5). Historical control trials of different drug combinations, including the standard-of-care ("SOC") of FOLFIRI with bevacizumab, in similar patient populations have shown ORR and mPFS of 5 – 13% and ~4.5 – 5.7 months, respectively.

19
• A subgroup analysis of patients who were bevacizumab naïve vs patients who had received prior bevacizumab in 1st line therapy showed that patients who were bevacizumab naïve (n=13) had an ORR of 69% and mPFS of 13.5 months , which is well above historical controls. In contrast, patients previously treated with bevacizumab (n=35) had an ORR of 23% and mPFS of 7.8 months.

Phase 2 Randomized Clinical Trial in KRAS-mutated mCRC (the ONSEMBLE trial)

The ONSEMBLE trial (CRDF-003), is a Phase 2 open-label, randomized multi-center clinical trial of onvansertib in combination with standard of care FOLFIRI and bevacizumab (Avastin®) for the second line treatment of patients with KRAS-mutated mCRC, which will be conducted at approximately 40 clinical trial sites across the U.S.

The primary objective of the ONSEMBLE trial is to evaluate onvansertib’s safety and efficacy in combination with the standard-of-care FOLFIRI/bevacizumab regimen in patients with second-line KRAS/NRAS-mutated mCRC. The trial is expected to enroll approximately 150 patients who will be randomized 1:1:1 to receive standard-of-care alone, standard-of-care plus 20 mg onvansertib, or standard-of-care plus 30 mg onvansertib, with onvansertib administered on days 1-5 and 15-19 of 28-day treatment cycles.

The primary endpoint of the trial is objective response rate. Progression-free survival and duration of response will be key secondary endpoints. Activation of the trial is expected in Q4 2022, with topline data anticipated in 2H 2024.

Phase 2 Clinical Trial in mPDAC

CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan (Onivyde ® ), leucovorin, and fluorouracil for second line treatment of patients with mPDAC, which is being conducted at six clinical trial sites across the U.S. – The Mayo Clinic Cancer Centers (Arizona, Minnesota, and Florida), Kansas University Medical Center, Inova Schar Cancer Institute, and the University of Nebraska Medical Center. The first patient was dosed in June 2021.

The objective of this trial is to assess the safety and preliminary efficacy of onvansertib in combination with nanoliposomal irinotecan (Onyvide ® ), 5-FU and leucovorin as a second-line treatment in patients with mPDAC who have failed first-line gemcitabine-based therapy. The trial is expected to enroll approximately 45 patients.

Preliminary data presented on September 12, 2022 provided an update of the ongoing CRDF-001 phase 2 open label clinical trial in mPDAC:

• Preliminary data from 5 evaluable patients showed 1 patient achieving an initial partial response (PR) and 3 patients achieving stable disease (SD);

• The 4 patients achieving SD or PR remain on study; the fifth evaluable patient discontinued treatment due to disease progression and an additional 3 patients remain on study awaiting their first post-baseline scan;

• Additional data is anticipated in mid 2023.


Phase 1b/2 Investigator-Initiated Clinical Trial in TNBC

A single-arm, Phase 1b/2 trial of onvansertib in combination with paclitaxel in patients with unresectable locally advanced or metastatic TNBC is open for enrollment at Dana Farber Cancer Institute ("DFCI"). In Phase 1b, approximately 14-16 patients will be treated with different doses of onvansertib in combination with a fixed dose of paclitaxel to determine the maximum tolerated dose and RP2D of onvansertib. In Phase 2, approximately 34 patients will be treated with the selected onvansertib RP2D in combination with paclitaxel.

The primary endpoint of Phase 2 of the trial is ORR, with PFS included as a secondary endpoint. Preliminary data from the trial are expected in Q4 2023 or Q1 2024. For more information, please visit NCT05383196 at www.clinicialtrials.gov .

20
Phase 2 Investigator-Initiated Clinical Trial in SCLC

A single-arm, two-stage, Phase 2 trial of onvansertib monotherapy in patients with relapsed SCLC is open for enrollment at the University of Pittsburgh Medical Center ("UPMC"). The trial is designed to enroll 15 patients in Stage 1, with the study proceeding to Stage 2 if 2 or more Stage 1 patients achieve an objective response. Stage 2 is designed to enroll an additional 20 patients. The primary endpoint of the trial is ORR, while key secondary endpoints include PFS and overall survival. Preliminary data from the trial are expected in mid 2023. For more information, please visit NCT05450965.

Critical Accounting Policies
Our accounting policies are described in ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS of our Annual Report on Form 10-K as of and for the year ended December 31, 2021, filed with the SEC on February 24, 2022. There have been no changes to our critical accounting policies since December 31, 2021.

RESULTS OF OPERATIONS
Three Months Ended September 30, 2022 and 2021
Revenues
Total revenues were $93,000 for the three months ended September 30, 2022, as compared to $86,000 for the prior period. Revenues are from our sales-based or usage-based royalties on other intellectual property licenses, unrelated to onvansertib. Revenue recognition of the royalty depends on the timing and overall sales activities of the licensees.
Research and Development Expenses
Research and development expenses consisted of the following:
Three Months Ended September 30,
(in thousands) 2022 2021 Increase (Decrease)
Salaries and staff costs $ 1,000 $ 521 $ 479
Stock-based compensation 286 174 112
Clinical trials, outside services, and lab supplies 4,279 3,104 1,175
Facilities and other 444 355 89
Total research and development $ 6,009 $ 4,154 $ 1,855
Research and development expenses increased by $1.9 million for the three months ended September 30, 2022, compared to the same period in 2021. The overall increase in expenses was primarily related to chemistry, manufacturing, and controls ("CMC") and clinical pharmacology for studies to support the development of our lead drug candidate, onvansertib. Salaries and staff costs increased primarily due to additional hires in senior management and our clinical operations team (research and development average headcount grew by 73% over the comparative period).

Selling, General and Administrative Expenses
Selling, general and administrative expenses consisted of the following:
Three Months Ended September 30,
(in thousands) 2022 2021 Increase (Decrease)
Salaries and staff costs $ 808 $ 671 $ 137
Stock-based compensation 751 766 (15)
Outside services and professional fees 840 914 (74)
Facilities and other 678 579 99
Total selling, general and administrative $ 3,077 $ 2,930 $ 147
21
Selling, general and administrative expenses increased by $0.1 million for the three months ended September 30, 2022, compared to the same period in 2021. Salaries and staff costs increased due to merit increases and higher headcount (average headcount grew by 27% over the comparative period). Facilities and other costs increased due to higher insurance costs and the amending of our operating lease. The decrease in outside services and professional fees was due to recruiting fees incurred for the recruitment of officers and directors in the prior period.

Net Loss
Net loss and per share amounts were as follows:

Three Months Ended September 30,
(in thousands, except per share amounts) 2022 2021 Increase (Decrease)
Net loss $ (8,571) $ (6,913) $ 1,658
Preferred stock dividend (6) (6) —
Net loss attributable to common shareholders $ (8,577) $ (6,919) $ 1,658
Net loss per common share — basic and diluted $ (0.20) $ (0.17) $ 0.03
Weighted average shares outstanding — basic and diluted 43,333 39,552 3,781
The $1.7 million increase in net loss attributable to common shareholders was primarily the result of an increase of operating expenses for the three months ended September 30, 2022, compared to the same period in the prior year. The $0.03 increase in net loss per share was impacted by the increase in basic weighted average shares outstanding resulting primarily from the issuance of approximately 3.8 million shares of common stock and common stock equivalents from October 1, 2021 through September 30, 2022.

Nine Months Ended September 30, 2022 and 2021

Revenues
Total revenues were $258,000 for the nine months ended September 30, 2022, as compared to $226,000 for the prior period. Revenues are from our sales-based or usage-based royalties on other intellectual property licenses, unrelated to onvansertib. Revenue recognition of the royalty depends on the timing and overall sales activities of the licensees.
Research and Development Expenses
Research and development expenses consisted of the following:
Nine Months Ended September 30,
(in thousands) 2022 2021 Increase (Decrease)
Salaries and staff costs $ 3,131 $ 1,095 $ 2,036
Stock-based compensation 746 286 460
Clinical trials, outside services, and lab supplies 15,699 9,510 6,189
Facilities and other 1,089 661 428
Total research and development $ 20,665 $ 11,552 $ 9,113
Research and development expenses increased by $9.1 million for the nine months ended September 30, 2022, compared to the same period in 2021. The overall increase in expenses was primarily related to CMC and clinical pharmacology for studies to support the development of our lead drug candidate, onvansertib. Salaries and staff costs increased primarily due to additional hires in senior management and our clinical operations team (research and development average headcount grew by 108% over the comparative period). The increase in stock-based compensation is primarily due to additional stock option grants to employees granted subsequent to the prior period.

22
Selling, General and Administrative Expenses
Selling, general and administrative expenses consisted of the following:
Nine Months Ended September 30,
(in thousands) 2022 2021 Increase (Decrease)
Salaries and staff costs $ 2,460 $ 1,752 $ 708
Stock-based compensation 2,498 1,958 540
Outside services and professional fees 3,119 2,799 320
Facilities and other 2,026 1,494 532
Total selling, general and administrative $ 10,103 $ 8,003 $ 2,100
Selling, general and administrative expenses increased by $2.1 million for the nine months ended September 30, 2022, compared to the same period in 2021. Salaries and staff costs increased due to merit increases and higher headcount (average headcount grew by 37% over the comparative period). The increase in stock-based compensation is primarily due to additional stock option grants to employees granted subsequent to the prior period. Facilities and other costs increased due to higher insurance costs and the amending of our operating lease.

Net Loss
Net loss and per share amounts were as follows:

Nine Months Ended September 30,
(in thousands, except per share amounts) 2022 2021 Increase (Decrease)
Net loss $ (30,007) $ (18,849) $ 11,158
Preferred stock dividend (18) (18) —
Net loss attributable to common shareholders $ (30,025) $ (18,867) $ 11,158
Net loss per common share — basic and diluted $ (0.69) $ (0.49) $ 0.20
Weighted average shares outstanding — basic and diluted 43,291 38,501 4,790
The $11.2 million increase in net loss attributable to common shareholders was primarily the result of an increase in operating expenses for the nine months ended September 30, 2022, compared to the same period in the prior year. The $0.20 increase in basic net loss per share was impacted by the increased net loss attributable to common shareholders and the increase in weighted average shares outstanding resulting primarily from the issuance of approximately 3.8 million shares of common stock from October 1, 2021 through September 30, 2022.

LIQUIDITY AND CAPITAL RESOURCES

Net cash used in operating activities for the nine months ended September 30, 2022, was $24.4 million, compared to $15.7 million for the nine months ended September 30, 2021. Our use of cash was primarily a result of the net loss of $30.0 million for the nine months ended September 30, 2022, adjusted for non-cash items related to stock-based compensation of $3.2 million, amortization of premiums on short-term investments of $0.7 million, and release of clinical trial funding commitment of $0.1 million. The net change in our operating assets and liabilities was $1.4 million increasing cash used in operations. At our current and anticipated level of operating loss, we expect to continue to incur an operating cash outflow for the next several years.

Net cash provided by investing activities was $31.1 million primarily related to sales and maturities in excess of purchases of marketable securities, offset by purchases of capital equipment during the nine months ended September 30, 2022, compared to net cash used in investing activities of $122.7 million for net purchases of marketable securities during the same period in 2021.

23
Net cash provided in financing activities was $75,000 from the exercise of stock options during the nine months ended September 30, 2022, compared to $20.5 million of proceeds from the sale of common stock and proceeds from warrant exercises for the same period in 2021.

As of September 30, 2022, and December 31, 2021, we had working capital of $111.5 million and $139.6 million, respectively.

We have incurred net losses since our inception and have negative operating cash flows. As of September 30, 2022, we had $114.3 million in cash, cash equivalents and short-term investments and we believe we have sufficient cash to meet our funding requirements for at least the next 12 months following the issuance date of this Quarterly Report on Form 10-Q. Based on our current projections we expect that our capital resources are sufficient to fund our operations into 2025.

Our drug development efforts are in their early stages, and we cannot make estimates of the costs or the time that our development efforts will take to complete, or the timing and amount of revenues related to the sale of our drug candidates. The risk of completion of any program is high because of the many uncertainties involved in developing new drug candidates to market, including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols, extended regulatory approval and review cycles, our ability to raise additional capital, the nature and timing of research and development expenses, and competing technologies being developed by organizations with significantly greater resources.

For the foreseeable future, we expect to continue to incur losses and require additional capital to further advance our clinical trial programs and support our other operations. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we can raise additional funds by issuing equity securities, our stockholders may experience additional dilution.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We have performed an evaluation under the supervision and with the participation of our management, including our principal executive officer (CEO) and principal financial officer (CFO), of the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2022, to provide reasonable assurance that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all errors and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company have been detected.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting during the three months ended September 30, 2022, that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
24
PART II.  OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS
None.

ITEM 1A. RISK FACTORS
There have been no material changes from the risk factors disclosed in our Form 10-K for the year ended December 31, 2021.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None .

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS
Exhibit
Number 		Description of Exhibit
31.1
31.2
32.1
32.2
101.INS Inline XBRL Instance Document
101.SCH Inline XBRL Taxonomy Extension Schema
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase
101.LAB Inline XBRL Taxonomy Extension Labels Linkbase
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase
104 Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, is formatted in Inline XBRL

25
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CARDIFF ONCOLOGY, INC.
November 3, 2022 By: /s/ Mark Erlander
Mark Erlander
Chief Executive Officer
CARDIFF ONCOLOGY, INC.
November 3, 2022 By: /s/ James Levine
James Levine
Chief Financial Officer

26
TABLE OF CONTENTS